Immuneering Corporation (IMRX)
NASDAQ: IMRX · Real-Time Price · USD
5.15
+0.17 (3.41%)
Mar 6, 2026, 10:32 AM EST - Market open
Immuneering Employees
Immuneering had 66 employees as of December 31, 2024. The number of employees decreased by 2 or -2.94% compared to the previous year.
Employees
66
Change (1Y)
-2
Growth (1Y)
-2.94%
Revenue / Employee
n/a
Profits / Employee
-$1,037,498
Market Cap
332.54M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 66 | -2 | -2.94% |
| Dec 31, 2023 | 68 | -5 | -6.85% |
| Dec 31, 2022 | 73 | 9 | 14.06% |
| Dec 31, 2021 | 64 | 38 | 146.15% |
| Dec 31, 2020 | 26 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Puma Biotechnology | 172 |
| X4 Pharmaceuticals | 143 |
| Nautilus Biotechnology | 124 |
| Foghorn Therapeutics | 112 |
| Rezolute | 75 |
| Shattuck Labs | 44 |
| Protara Therapeutics | 33 |
| Avalo Therapeutics | 23 |
IMRX News
- 2 hours ago - Immuneering Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates - GlobeNewsWire
- 3 days ago - Immuneering to Present at the Leerink Global Healthcare Conference - GlobeNewsWire
- 15 days ago - Immuneering to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference - GlobeNewsWire
- 2 months ago - Immuneering: Strong Buy Despite Decline In Share Price On Atebimetinib Data - Seeking Alpha
- 2 months ago - Immuneering Pancreatic Cancer Trial Touts Encouraging Survival Data, But Stock Moves Lower - Benzinga
- 2 months ago - Immuneering Corporation (IMRX) Discusses Positive 12-Month Overall Survival Update From Phase IIa Trial of Atebimetinib in First-Line Pancreatic Cancer Transcript - Seeking Alpha
- 2 months ago - Immuneering Announces Exceptional 64% Overall Survival At 12 Months in First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP - GlobeNewsWire
- 2 months ago - Immuneering to Announce 12-Month Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on January 7, 2026 - GlobeNewsWire